Comparative Pharmacology
Head-to-head clinical analysis: BRONKOSOL versus DILOR 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOSOL versus DILOR 400.
BRONKOSOL vs DILOR-400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal (70% unchanged), hepatic metabolism (30%)
Category C
Category C
Bronchodilator
Bronchodilator